Coach vs. Kors: Bat...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$15.12 -0.50 | -3.20%
06/01/12 - 04:00 PM ET
Company Income Statement
| Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | |
| Sales | 389.98M | 186.64M | 178.28M | 326.84M |
| Cost of Sales | 105.05M | 43.53M | 24.41M | 33.13M |
| Gross Operating Profit | 284.93M | 143.11M | 153.87M | 293.71M |
| Selling, General, and Administrative Expenses | 137.63M | 82.85M | 76.51M | 59.01M |
| Research & Development | 141.89M | 97.24M | 95.36M | 89.48M |
| Operating Income before D & A (EBITDA) | 5.40M | -36.98M | -18.01M | 145.22M |
| Depreciation & Amortization | 93.68M | 8.65M | 25.03M | 10.26M |
| Interest Income | 1.52M | 2.73M | 4.67M | 11.40M |
| Other Income - Net | 484.00K | -290.00K | -360.00K | -1.59M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -86.28M | -43.19M | -38.73M | 144.77M |
| Interest Expense | 28.11M | 3.30M | 5.97M | 13.76M |
| Pre-Tax Income | -114.39M | -46.49M | -44.70M | 131.01M |
| Income Taxes | -714.00K | -951.00K | -5.08M | 507.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -113.68M | -45.54M | -39.63M | 130.50M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -113.68M | -45.54M | -39.63M | 130.50M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -113.68M | -45.54M | -39.63M | 130.50M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-113.68M | -45.54M | -39.63M | 130.50M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -113.68M | -45.54M | -39.63M | 130.50M |
| Basic EPS from Continuing Ops. | -0.99 | -0.48 | -0.42 | 1.37 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.99 | -0.48 | -0.42 | 1.37 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.99 | -0.48 | -0.42 | 1.37 |
| Basic Normalized Net Income/Share | -0.99 | -0.48 | -0.42 | 1.37 |
| EPS fr Continuing Ops. | -0.99 | -0.48 | -0.42 | 1.36 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.99 | -0.48 | -0.42 | 1.36 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.99 | -0.48 | -0.42 | 1.36 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.99 | -0.48 | -0.42 | 1.36 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
Latest ALKS Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Housing Comeback 05.10.12 | 08:05 pm
- 5 Stocks Insiders Love Right Now 05.02.12 | 11:05 am
- 8 Stocks Rising on Monster Volume 03.28.12 | 12:03 pm
- Insiders Trading TZYM, ALKS, CAKE 03.15.12 | 08:03 am
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 05.31.12 | 07:05 am
- Alkermes Announces Results From Phase 2 Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation - Business Wire 05.30.12 | 04:05 pm
- Alkermes Presents Positive Clinical Data Of ALKS 5461 At 52nd Annual New Clinical Drug Evaluation Unit Meeting - Business Wire 05.29.12 | 04:05 pm
- Alkermes Plc Completes Secondary Offering Of 24,150,000 Ordinary Shares Held By Elan - Business Wire 03.13.12 | 11:03 am
- Alkermes Plc Prices Secondary Offering Of 21,000,000 Ordinary Shares Held By Elan - Business Wire 03.08.12 | 09:03 am
- Alkermes Plc Announces A Secondary Offering Of 13,900,000 Ordinary Shares Held By Elan - Business Wire 03.07.12 | 04:03 pm
- Alkermes Appoints Mark Stejbach As Chief Commercial Officer - Business Wire 03.05.12 | 07:03 am
- Alkermes’ Corporate Presentation To Be Webcast At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 04:02 pm
- Alkermes Files Resale Shelf Registration In Connection With Elan Shareholder Agreement - Business Wire 02.16.12 | 04:02 pm
- BYDUREONâ¢, First And Only Once-Weekly Type 2 Diabetes Treatment, Now Available In U.S. Pharmacies - PR Newswire 02.13.12 | 08:02 am
Partner Headlines for ALKS
- Healthcare Biz Recap: Teva's Counterfeit Problem, Hopes for Bristol-Myers - Wall St. Cheat Sheet 05.30.12 | 07:05 am
- Alkermes Earnings Call Insights: Adjusted EBITDA, VIVITROL - Wall St. Cheat Sheet 05.29.12 | 01:05 pm
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan - Benzinga 03.07.12 | 04:03 pm
- Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory - Seeking Alpha 02.22.12 | 08:02 am
- The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases - Zacks 02.16.12 | 09:02 am
- Analyzing Friday's Noteworthy Insider Buys And Sells - Seeking Alpha 02.12.12 | 07:02 am
